Nonvalvular Atrial Fibrillation
Next-generation LAA closure device for patients with nonvalvular AF gains FDA approval
Boston Scientific announced it received FDA approval for its next-generation left atrial appendage closure device indicated to reduce risk for stroke in certain patients with nonvalvular atrial fibrillation.
Direct oral anticoagulants correlate with reduced kidney failure risk
Compared with warfarin, direct oral anticoagulants correlated with a reduced risk for kidney failure and declined kidney function among patients with nonvalvular atrial fibrillation, according to a retrospective study.
Kidney disease progression risk lower with DOACs vs. vitamin K antagonists in AF
Among adults with nonvalvular atrial fibrillation, direct oral anticoagulant initiation was associated with lower risk for renal failure or progression of chronic kidney disease compared with vitamin K antagonist initiation, data show.
Data show LAA closure safe in nonvalvular AF with HF
A database review showed left atrial appendage closure with the Watchman device is safe in adults with HF and atrial fibrillation, who experienced in-hospital mortality and CV complication rates similar to those without HF.
LIGATE
Feasibility and safety profile of a second-generation LAAC device (Ultraseal, Cardia) in nonvalvular atrial fibrillation.
Next-generation LAA closure device ‘promising alternative’ for adults with nonvalvular AF
Among patients with nonvalvular atrial fibrillation, left atrial appendage closure with a second‐generation device was associated with high success rates and a low risk for procedure‐related adverse events, researchers reported.
Study examines dosing for patients on dialysis with nonvalvular atrial fibrillation
Frail patients less likely to receive certain blood thinners, despite recommendations
Among patients with nonvalvular atrial fibrillation, those with frailty were less likely to receive an anticoagulant and, if anticoagulated, were more likely to receive warfarin than a direct oral anticoagulant, researchers reported.
More adverse events, longer hospital stays for women undergoing LAA occlusion vs. men
Women who underwent left atrial appendage occlusion for nonvalvular atrial fibrillation experienced more adverse in-hospital outcomes and longer hospital stays compared with men, according to data published in JAMA Cardiology.
In nonvalvular AF, prediabetes confers elevated risk for stroke
Diabetes and prediabetes were associated with increased risk for stroke in patients with nonvalvular atrial fibrillation, according to a study published in the Journal of the American College of Cardiology.